Apotex

Judge Sidney Stein in U.S. court in New York ruled Tuesday that Apotex is liable for half of the $884.4 million in net sales it generated from generic Plavix, under the terms of an agreement both sides had reached prior to a patent dispute trial.

Judge Rules Apotex Owes $442.2 Million in Plavix Dispute Peter Loftus 2010

Judge Sidney Stein in U.S. court in New York ruled that Apotex is liable for half of the $884.4 million in net sales it generated from generic Plavix, under the terms of an agreement both sides had reached prior to a patent dispute trial.

FDA Repeats Plavix Warning Alicia Mundy 2010

His charges result from a deal cut between Bristol-Myers and a company called Apotex over the blood-thinning drug Plavix.

B2fxxx 2009

His charges result from a deal cut between Bristol-Myers and a company called Apotex over the blood-thinning drug Plavix.

Archive 2009-06-07 2009

Apotex, Inc., and Torpharm, Inc., (collectively, "Apotex") and Impax Laboratories, Inc., appeal judgments entered against them by the United States District Court for the Southern District of New York.

Intellectual Property and Tech Law Reports 2008

A U.S. appeals court has reduced by more than $100 million the payment Apotex Corp. must make to Sanofi and Bristol-Myers Squibb Co. for having sold generic copies of the popular blood thinner Plavix in violation of a patent in 2006.

Apotex Payment to Sanofi, Bristol in Plavix Case Reduced Peter Loftus 2011

Sanofi and Bristol sought damages from Apotex, but a prior agreement between the two sides limited the amount of damages to 50% of Apotex's net sales of its generic Plavix—or $442.2 million.

Apotex Payment to Sanofi, Bristol in Plavix Case Reduced Peter Loftus 2011

Sanofi and Bristol sought damages from Apotex, but a prior agreement between the two sides limited the amount of damages to 50% of Apotex's net sales of its generic Plavix—or $442.2 million.

Corporate Watch 2011

A proposed settlement of the ensuing patent litigation fell apart in 2006, and Apotex flooded the market with generic copies, which hurt sales of the branded drug.

Corporate Watch 2011

Apotex had challenged the validity of a U.S. patent for Plavix nearly a decade ago in applying for regulatory approval to sell a generic version.

Apotex Payment to Sanofi, Bristol in Plavix Case Reduced Peter Loftus 2011